RxDoctor Payments Data

Andrea Yonge, MD

Ophthalmology · Portland, ORNPI 1144644543

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 39.4% of the total. Reporting peaked in 2024 at $1,109 and has fallen 73.9% since, to $289 in 2025.

$4,023in general payments, 2019–2025

Across 63 payments — averaging $63.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Alcon$1K
  • Rxsight Inc$402
  • Johnson & Johnson Surgical Vision, Inc.$245
  • Sight Sciences, Inc.$206
  • Regeneron Healthcare Solutions, Inc.$125
  • plus $182 from 4 others

What the payments were for

  • Food & beverage$4,023100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,023 in reported general payments places this provider in the 85th percentile of 248 ophthalmology providers in Oregon.

See all ophthalmology providers in Oregon

Medicare billing

Part B allowed, 2024
$166,192
Medicare patients
446
Services billed
1,510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate70$25,511
Prednisolone Acetate470$20,746
Latanoprost944$11,269
LumiganBimatoprost21$10,727
Brinzolamide50$9,332
Travoprost66$7,628
RestasisCyclosporine15$6,779
Ketorolac Tromethamine371$6,545
Timolol Maleate224$6,306
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat312$5,003
Brimonidine Tartrate245$4,873
Ofloxacin305$3,517
Difluprednate15$2,626
Dorzolamide Hcl127$2,369
ValacyclovirValacyclovir Hcl32$2,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rhopressa$110$25,51170 claims
AbbVieLumigan, Restasis$1,584$17,50636 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 248 ophthalmology providers in Oregon.

Other ophthalmology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →